ES2904880T3 - Terapia combinada con inhibidores de Notch y de PD-1 o PD-L1 - Google Patents

Terapia combinada con inhibidores de Notch y de PD-1 o PD-L1 Download PDF

Info

Publication number
ES2904880T3
ES2904880T3 ES17726073T ES17726073T ES2904880T3 ES 2904880 T3 ES2904880 T3 ES 2904880T3 ES 17726073 T ES17726073 T ES 17726073T ES 17726073 T ES17726073 T ES 17726073T ES 2904880 T3 ES2904880 T3 ES 2904880T3
Authority
ES
Spain
Prior art keywords
cancer
oxo
use according
lymphoblastic leukemia
carcinoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17726073T
Other languages
English (en)
Spanish (es)
Inventor
Mark Harrath Bender
Hong Gao
Bharvin Kumar Patel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2904880T3 publication Critical patent/ES2904880T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES17726073T 2016-05-20 2017-05-16 Terapia combinada con inhibidores de Notch y de PD-1 o PD-L1 Active ES2904880T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662339363P 2016-05-20 2016-05-20
PCT/US2017/032790 WO2017200969A1 (en) 2016-05-20 2017-05-16 Combination therapy with notch and pd-1 or pd-l1 inhibitors

Publications (1)

Publication Number Publication Date
ES2904880T3 true ES2904880T3 (es) 2022-04-06

Family

ID=58772978

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17726073T Active ES2904880T3 (es) 2016-05-20 2017-05-16 Terapia combinada con inhibidores de Notch y de PD-1 o PD-L1

Country Status (15)

Country Link
US (2) US10688104B2 (enExample)
EP (1) EP3458091B1 (enExample)
JP (1) JP7194022B2 (enExample)
KR (1) KR102463617B1 (enExample)
CN (2) CN109475629A (enExample)
AU (1) AU2017268187A1 (enExample)
BR (1) BR112018073673A2 (enExample)
CA (1) CA3025024A1 (enExample)
ES (1) ES2904880T3 (enExample)
IL (1) IL263110B (enExample)
MA (1) MA45025A (enExample)
MX (1) MX2018013941A (enExample)
SG (1) SG11201810268YA (enExample)
WO (1) WO2017200969A1 (enExample)
ZA (1) ZA201807585B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI609687B (zh) 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療
CA2991976A1 (en) 2015-07-13 2017-01-19 Cytomx Therapeutics, Inc. Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
KR102418766B1 (ko) 2016-04-12 2022-07-08 일라이 릴리 앤드 캄파니 암 치료에 사용하기 위한 Notch 및 PI3K/mTOR 억제제의 조합 요법
KR102418765B1 (ko) 2016-04-12 2022-07-08 일라이 릴리 앤드 캄파니 암 치료를 위한 Notch 및 CDK4/6 억제제의 조합 요법
US10688104B2 (en) 2016-05-20 2020-06-23 Eli Lilly And Company Combination therapy with Notch and PD-1 or PD-L1 inhibitors
EP3525796A1 (en) 2016-10-12 2019-08-21 Eli Lilly and Company Targeted treatment of mature t-cell lymphoma
JP2020507605A (ja) 2017-02-17 2020-03-12 フレッド ハッチンソン キャンサー リサーチ センター Ｂｃｍａ関連癌および自己免疫疾患の治療のための併用療法
EP3706754A1 (en) 2017-11-06 2020-09-16 Juno Therapeutics, Inc. Combination of a cell therapy and a gamma secretase inhibitor
JP2021506968A (ja) * 2017-12-18 2021-02-22 デビオファーム・インターナショナル・エス・アーＤｅｂｉｏｐｈａｒｍ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｓ．Ａ． 癌を治療するためのアゴニスト抗ＰＤ−１抗体とＧｎＲＨアゴニスト又はアンタゴニストとの併用
JP2022553421A (ja) * 2019-10-28 2022-12-22 エンジーケム ライフサイエンシーズ コーポレーション がんの処置のための方法および組成物
KR20240004519A (ko) * 2021-04-28 2024-01-11 아센타위츠 파마슈티컬즈 리미티드 면역관문 억제제와 함께 akr1c3-활성화 화합물을 사용하는 병용 요법
CN121712509A (zh) 2023-05-04 2026-03-20 锐新医药公司 用于ras相关疾病或病症的组合疗法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
IL327306A (en) 2023-10-12 2026-05-01 Revolution Medicines Inc Macrocyclic RAS inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR199901343T2 (xx) 1996-12-23 1999-09-21 Elan Pharmaceuticals, Inc. Sikloalkil, laktam, lakton ve ilgili bile�ikler, bunlar� i�eren farmas�tik bile�imler ve b�yle bile�ikler kullan�larak �-amiloid peptidinin sal�nmas�n� ve/veya sentezini inhibe etmek i�in y�ntemler.
WO2000020576A2 (en) 1998-10-02 2000-04-13 The Government Of The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services, The National Institutes Of Health Methods and compositions for inducing differentiation and apotosis in cells that overexpess the notch protein
WO2004056875A1 (en) 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
GB0303663D0 (en) * 2003-02-18 2003-03-19 Lorantis Ltd Assays and medical treatments
PL2161336T5 (pl) 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
CA2612241C (en) * 2005-07-01 2018-11-06 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
WO2007004743A1 (en) 2005-07-05 2007-01-11 Fujifilm Corporation Copolymer and polymerizable composition
DE102006002966A1 (de) * 2006-01-21 2007-07-26 Schaeffler Kg Laufscheibe mit integrierter Wälzkörperlaufbahn
US8633179B2 (en) 2007-03-13 2014-01-21 The Trustees Of Columbia University In The City Of New York Synergistic interaction of NOTCH-1 inhibitors with glucocorticoids
SG10201508035TA (en) 2007-03-28 2015-10-29 Pharmacyclics Inc Inhibitors of bruton's tyrosine kinase
KR101586617B1 (ko) 2007-06-18 2016-01-20 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
CN101778826B (zh) 2007-08-14 2012-10-31 伊莱利利公司 作为γ分泌酶抑制剂的氮杂*衍生物
MA33076B1 (fr) 2008-01-11 2012-03-01 Hoffmann La Roche Utilisation d'un inhibiteur de la gamma-secretase pour le traitement du cancer
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
ES2545609T3 (es) 2008-08-25 2015-09-14 Amplimmune, Inc. Composiciones de antagonistas de PD-1 y métodos de uso
EP4209510B1 (en) 2008-12-09 2024-01-31 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
EP3192811A1 (en) 2009-02-09 2017-07-19 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
EP2470054B1 (de) 2009-08-26 2013-12-04 FrXsh AG Vorrichtung und verfahren zum mischen von mischgut
US8637493B2 (en) 2009-11-12 2014-01-28 University Of Massachusetts Methods for treating glioblastoma
NO2504364T3 (enExample) 2009-11-24 2018-01-06
CN102085372A (zh) 2009-12-04 2011-06-08 中国医学科学院基础医学研究所 Notch通路抑制剂用于治疗mTOR活化导致的肿瘤的用途
CA2802344C (en) * 2010-06-18 2023-06-13 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
JO3003B1 (ar) 2011-01-14 2016-09-05 Lilly Co Eli مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor
AR087107A1 (es) * 2011-07-27 2014-02-12 Lilly Co Eli Compuesto inhibidor de la señalizacion de la trayectoria notch
EP2739358B1 (en) * 2011-08-01 2018-11-28 F.Hoffmann-La Roche Ag Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
US9624298B2 (en) 2011-11-28 2017-04-18 Merck Patent Gmbh Anti-PD-L1 antibodies and uses thereof
WO2014193898A1 (en) * 2013-05-31 2014-12-04 Merck Sharp & Dohme Corp. Combination therapies for cancer
US9698876B2 (en) 2013-07-23 2017-07-04 Telefonaktiebolaget Lm Ericsson (Publ) Transmission mode allocation in LTE networks
US9827309B2 (en) * 2013-08-20 2017-11-28 Merck Sharp & Dohme Corp. Treating cancer with a combination of a PD-1 antagonist and dinaciclib
GB201317929D0 (en) 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
WO2015117164A1 (en) * 2014-02-03 2015-08-06 Memorial Sloan-Kettering Cancer Center Tumor-associated macrophages and methods and compositions for targeting cancer therapy and identifying potential responders
US10092645B2 (en) * 2014-06-17 2018-10-09 Medimmune Limited Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy
BR112017000130A2 (pt) 2014-07-11 2018-01-09 Genentech Inc método para atenuar a toxicidade associada à inibição da via de notch e método de tratamento do câncer
MY181834A (en) 2014-07-21 2021-01-08 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
US9465158B2 (en) * 2014-09-04 2016-10-11 National Taiwan Normal University Light-guide coupler for modulating angular and spatial distributions of light source
WO2016040882A1 (en) * 2014-09-13 2016-03-17 Novartis Ag Combination therapies of egfr inhibitors
MX389823B (es) * 2014-10-27 2025-03-20 Fred Hutchinson Cancer Center Composiciones y metodos para reforzar la eficacia de inmunoterapia celular adoptiva.
US20160176962A1 (en) * 2014-10-31 2016-06-23 Oncomed Pharmaceuticals, Inc. Combination Therapy For Treatment Of Disease
EP3872094A3 (en) 2014-12-05 2021-12-08 Memorial Sloan Kettering Cancer Center Antibodies targeting b-cell maturation antigen and methods of use
EP3280795B1 (en) 2015-04-07 2021-03-24 Novartis AG Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
TWI609687B (zh) 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療
EP3662909A1 (en) 2015-07-24 2020-06-10 Oncotracker, Inc. Gamma secretase modulators for the treatment of immune system dysfunction
KR102418766B1 (ko) 2016-04-12 2022-07-08 일라이 릴리 앤드 캄파니 암 치료에 사용하기 위한 Notch 및 PI3K/mTOR 억제제의 조합 요법
KR102418765B1 (ko) 2016-04-12 2022-07-08 일라이 릴리 앤드 캄파니 암 치료를 위한 Notch 및 CDK4/6 억제제의 조합 요법
US10688104B2 (en) 2016-05-20 2020-06-23 Eli Lilly And Company Combination therapy with Notch and PD-1 or PD-L1 inhibitors
US20190209581A1 (en) 2016-08-31 2019-07-11 Eli Lilly And Company Dosage regimen for treatment of solid tumors
EP3525796A1 (en) 2016-10-12 2019-08-21 Eli Lilly and Company Targeted treatment of mature t-cell lymphoma
US20200055948A1 (en) 2017-04-28 2020-02-20 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
EP3706754A1 (en) 2017-11-06 2020-09-16 Juno Therapeutics, Inc. Combination of a cell therapy and a gamma secretase inhibitor

Also Published As

Publication number Publication date
IL263110A (en) 2018-12-31
MX2018013941A (es) 2019-03-21
JP2019516733A (ja) 2019-06-20
SG11201810268YA (en) 2018-12-28
IL263110B (en) 2022-07-01
US20190192531A1 (en) 2019-06-27
WO2017200969A1 (en) 2017-11-23
MA45025A (fr) 2019-03-27
CN109475629A (zh) 2019-03-15
US10688104B2 (en) 2020-06-23
CN115845070A (zh) 2023-03-28
US20220008432A1 (en) 2022-01-13
CA3025024A1 (en) 2017-11-23
EP3458091B1 (en) 2021-11-17
KR20190008913A (ko) 2019-01-25
KR102463617B1 (ko) 2022-11-03
ZA201807585B (en) 2024-09-25
BR112018073673A2 (pt) 2019-02-26
JP7194022B2 (ja) 2022-12-21
EP3458091A1 (en) 2019-03-27
AU2017268187A1 (en) 2018-11-29
US11826317B2 (en) 2023-11-28

Similar Documents

Publication Publication Date Title
JP7194022B2 (ja) Ｎｏｔｃｈ阻害剤とＰＤ－１またはＰＤ－Ｌ１阻害剤との併用療法
JP2021020909A (ja) がんの治療のための方法、組成物、及びキット
CN114224889B (zh) 西奥罗尼联合免疫检查点抑制剂在抗肿瘤治疗中的应用
US12295962B2 (en) Polymorphic compounds and uses thereof
JP2025185043A (ja) 癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与
AU2019362050B2 (en) Combinations for immune-modulation in cancer treatment
JP2019510785A (ja) 癌を処置する方法
EP3380521A1 (en) Combination therapy for cancer
WO2020249018A1 (zh) 治疗驱动基因阳性肺癌的联用药物组合物
WO2020233602A1 (zh) 用于联合治疗小细胞肺癌的喹啉衍生物
KR20230026493A (ko) Hif-2알파 억제제 및 렌바티닙의 조합물을 사용하여 암 또는 폰-히펠 린다우병을 치료하는 방법
JP7747307B2 (ja) 抗癌剤耐性の軽減、及び抗癌剤の感受性の増強のための医薬組成物及びその使用
CN107949401A (zh) 联合施用酪氨酸激酶抑制剂来抑制表皮生长因子/表皮生长因子受体途径的方法及组合物
JP7504106B2 (ja) がんの処置のための組合せ物
TW201306833A (zh) 包含康布列塔司他汀（ｃｏｍｂｒｅｔａｓｔａｔｉｎｓ）族衍生物及西妥昔單抗（ｃｅｔｕｘｉｍａｂ）之組合
EP3897628A1 (en) Combination therapy for treatment of cancer
HK40004756A (en) Combination therapy with notch and pd-1 or pd-l1 inhibitors
HK40004756B (en) Combination therapy with notch and pd-1 or pd-l1 inhibitors
NZ788180A (en) Combination therapy with notch and pd-1 or pd-l1 inhibitors
HK40087480A (zh) 使用HIF-2α抑制剂和乐伐替尼的组合治疗癌症或VON-HIPPEL LINDAU病的方法
WO2021136523A1 (zh) 一种用于治疗肿瘤的药物组合及其应用
WO2020205458A1 (en) Combination therapy to treat cancer and uses thereof
TW201315461A (zh) 與放射線治療關聯之包含奧瑞布林（ｏｍｂｒａｂｕｌｉｎ）及西妥昔單抗（ｃｅｔｕｘｉｍａｂ）之抗腫瘤組合